NCT00151879View on ClinicalTrials.gov

Safety and Tolerability of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

May 31, 2006

Study Completion Date

May 31, 2006

Conditions
Epilepsies, Partial
Interventions
DRUG

SPM 927

Trial Locations (1)

Unknown

Schwarz, RTP

Sponsors

Lead Sponsor

UCB Pharma
All Listed Sponsors
lead

UCB Pharma

INDUSTRY